von Tobias Borgers | März 21, 2024 | Continuous Manufacturing
The pharmaceutical industry is confronting a variety of new and complex challenges in the face of globalization and changing market dynamics. The past decade has witnessed a decline in the discovery, approval and marketing of new chemical entities with fewer...
von Tobias Borgers | Feb. 14, 2024 | Boehringer
Boehringer Ingelheim is developing a biologicals development centre (BDC) at its facility in Biberach, Germany. Credit: Boehringer Ingelheim. A ground-breaking ceremony for the BDC was held in June 2018. Credit: Boehringer Ingelheim. BDC was inaugurated in April 2023....
von Tobias Borgers | Feb. 2, 2024 | Glaxo
When Matt Hill, PhD, was in graduate school, the human genome sequence was more or less finished and companies like 454 and Solexa were starting to make waves in next-gen sequencing (NGS). But Hill became more enamored with synthetic biology—engineering the genetic...
von Tobias Borgers | Feb. 2, 2024 | Glaxo
Omjjara is the first medicine in the EU specifically indicated for treating splenomegaly (enlarged spleen) or symptoms in adult myelofibrosis patients with moderate to severe anaemia Authorisation may address high unmet need, with nearly all myelofibrosis patients...
von Tobias Borgers | Jan. 10, 2024 | Markt
The need for innovation in drug-making Introduction to PAT in pharmaceutical manufacturing Real-time monitoring and control Reducing variability and waste References Further reading Technological innovations throughout the past several decades have transformed the...
